Coming soon. First inventory is in final QC.Coming soon
Compliance
You must be 21 or older. Agree to the following terms before accessing product information and pricing.
Research Use Policy Summary
For laboratory research use only. Not for human or veterinary consumption, diagnostic use, therapeutic use, or clinical use.

Growth Hormone Research
Accept the research disclaimer to view pricing and purchase options.
Product Usage Notice · This product is intended strictly for research and laboratory use only. It is designated for in vitro testing and experimental purposes. Any use involving human or animal consumption is prohibited by law. All information provided on this website is for educational purposes only. This product must only be handled by licensed, qualified professionals. It is not intended for use as a drug, food, or cosmetic, and must not be misused, mislabeled, or misrepresented as such. Read full Research Use Policy →
Technical specifications
Proprietary research blend combining ipamorelin (GHSR agonist) and CJC-1295 (GHRH analog), investigated for synergistic growth hormone pulse stimulation.
Ipamorelin, the First Selective Growth Hormone Secretagogue European Journal of Endocrinology Foundational paper establishing ipamorelin as a selective GHS-R1a agonist. Unlike GHRP-2 and GHRP-6, ipamorelin does not stimulate ACTH or cortisol, making it uniquely selective.
View StudyPharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in receptor pharmacology literature Pharmaceutical Research Published pharmacokinetic study characterizing GH release kinetics and half-life profile of ipamorelin. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.
View StudyIpamorelin Induces Longitudinal Bone Growth in Rats Growth Hormone & IGF Research Ipamorelin concentration-dependently increased longitudinal bone growth rate from 42 to 52 µm/day with pronounced concentration-dependent effects on growth pathway readouts in adult female rats.
View StudyProlonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295 in endocrine receptor pharmacology literature Journal of Endocrinology & Metabolism Published pharmacokinetic study characterizing sustained GH and IGF-I axis pathway markers and extended half-life of CJC-1295. Cited for scientific context only; does not represent product claims for this research compound.
View StudyPulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295 Journal of Endocrinology & Metabolism Published pharmacology literature examining GH secretagogue receptor signaling, IGF-I axis pathway markers, and pulsatility mechanisms. Cited for scientific context only; does not represent product claims for this research compound.
View StudyActivation of the GH/IGF-1 Axis by CJC-1295 in endocrine receptor pharmacology literature Growth Hormone & IGF Research Proteomic study characterizing serum protein pathway markers associated with GH/IGF-1 axis activation following CJC-1295 exposure. Cited for scientific context only; does not represent product claims for this research compound.
View StudyThis compound is supplied strictly for in-vitro and preclinical research use only. Primary applications include the areas below.
Tool compound for studying simultaneous GHSR and GHRH receptor engagement and synergistic GH release kinetics in preclinical models.
Investigates complementary receptor mechanisms and downstream signaling crosstalk between ghrelin receptor and GHRH receptor pathways in cell-based models.
Lot records organize identity, purity, storage context, and supporting COA documentation for laboratory intake review.
Lot documentation reports 99%+ purity and identity verification by the listed analytical method.
Explore